rapcabtagene autoleucel

Phase 2Cell therapy

rapcabtagene autoleucel is one of 135 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

134

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

MyositisActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Systemic SclerosisActive, not recruiting

Multiple SclerosisActive, not recruiting

Idiopathic Inflammatory MyopathiesActive, not recruiting

Progressive Multiple SclerosisRecruiting

Scleroderma, DiffuseRecruiting

Systemic Lupus ErythematosusPhase 2

Active, not recruiting

MyositisPhase 2

Active, not recruiting

Rheumatoid ArthritisPhase 1/Phase 2

Active, not recruiting

Systemic SclerosisPhase 2

Active, not recruiting

Multiple SclerosisPhase 1/Phase 2

Active, not recruiting

Idiopathic Inflammatory MyopathiesPhase 2

Active, not recruiting

Progressive Multiple SclerosisPreclinical

Recruiting

Scleroderma, DiffusePhase 2

Recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Rituxan

Roche

Preclinical

61 2

Cimzia

UCB

Preclinical

30 3

Simponi

Johnson & Johnson

Preclinical

19 4

rapcabtagene autoleucel

Novartis

Phase 2

1 5

Enbrel

IImmunex

Preclinical

64 6

Remicade

OOrganon and Co

Preclinical

43 7

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 8

Celexa

AbbVie

Preclinical

1 9

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 10

Cataflam

Novartis

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1/2Active, not recruiting

DLBCL

NCT03960840

Q3 2028

Phase 1Not yet recruiting

Residual Disease

NCT07443137

Q4 2028

Phase 1/2Recruiting

Rheumatoid Arthritis

NCT07048197

Q2 2030

Phase 2Recruiting

Phase 2

NCT06868290

PreclinicalRecruiting

Progressive Multiple Sclerosis

NCT06675864

Clinical

Trials by Indication[1]

DLBCL1 trial

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Active, not recruiting· Novartis logo

Novartis·Phase 1/2·NCT03960840·217 enrolled

Phase 21 trial

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

Recruiting· Novartis logo

Novartis·Phase 2·NCT06868290·126 enrolled

Multiple Sclerosis1 trial

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

Recruiting· Novartis logo

Novartis·Phase 1/2·NCT06617793·28 enrolled

Residual Disease1 trial

CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)

Not yet recruiting·SStanford University·Phase 1·NCT07443137·20 enrolled

Rheumatoid Arthritis1 trial

A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease

Recruiting· Novartis logo

Novartis·Phase 1/2·NCT07048197·27 enrolled

4 more indications

Systemic Lupus Erythematosus1 trial

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

Recruiting· Novartis logo

Novartis·Phase 2·NCT06581198·179 enrolled

Scleroderma, Diffuse1 trial

A Phase II, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants With Severe Refractory Diffuse Cutaneous Systemic Sclerosis

Recruiting· Novartis logo

Novartis·Phase 2·NCT06655896·96 enrolled

Progressive Multiple Sclerosis1 trial

An Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression, and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

Recruiting· Novartis logo

Novartis·Preclinical·NCT06675864·28 enrolled

Idiopathic Inflammatory Myopathies1 trial

A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Refractory Idiopathic Inflammatory Myopathies (IIM)

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT06665256·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for rapcabtagene autoleucel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rapcabtagene autoleucel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rapcabtagene autoleucel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: Novartis

rapcabtagene autoleucel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q3 2028

Q4 2028

Q2 2030

Trials by Indication[1]

DLBCL1 trial

Phase 21 trial

Multiple Sclerosis1 trial

Residual Disease1 trial

Rheumatoid Arthritis1 trial

Systemic Lupus Erythematosus1 trial

Scleroderma, Diffuse1 trial

Progressive Multiple Sclerosis1 trial

Idiopathic Inflammatory Myopathies1 trial

References

Drug Info

Quick Facts

Related News